1Day I.S.C.f.W.T (2014) Thrombosis: a major contributor to the global disease burden. Thromb Res134:931-938.

2Capodanno D, et al. (2019) Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol 74: 83-99.

3Poli KA, et al. (2000) Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation101: 264-9.

4Song C, et al. (2017) Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease. J Am Heart Assoc 6.

5Hrafnkelsdottir T, et al. (2004) Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension. Hypertension 44: 300- 304.

6Hrafnkelsdottir T, et al. (1998) Impaired capacity for endogenous fibrinolysis in essential hypertension. Lancet 352: 1597-1598.

7Newby DE, et al. (2001) Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: a direct link between endothelial dysfunction and atherothrombosis. Circulation 103: 1936-1941.

8Osterlund B, et al. (2008) Impaired myocardial t-PA release in patients with coronary artery disease. Acta Anaesthesiol Scand 52: 1375-1384.

9Van Guilder GP, et al. (2005) Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise. Am J Physiol Endocrinol Metab 289: 807-813.

10Kathiresan S, et al. (2006) Common genetic variation in five thrombosis genes and relations to plasma hemostatic protein level and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 26:1405-1412.

11Leadenhall P, et al. (2002) Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost 87: 105-109.

12Stead NW, et al. (1983) Venous thrombosis in a family with the defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. Am J Med 74: 33-39.

13Alessi MC, I Juhan-Vague (2004) Contribution of PAI-1 in cardiovascular pathology. Arch Mal Coeur Vaiss 97: 673-678.

14Robinson SD, et al. (2007) Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 27: 1651-1656.

15Thogersen AM, et al. (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98: 2241-2247.

16Dunoyer-Geindre S, EK Kruithof (2011) Epigenetic control of tissue-type plasminogen activator synthesis in human endothelial cells. Cardiovasc Res 90: 457-463.

17Larsson P, et al. (2013) Histone deacetylase inhibitors stimulate tissue-type plasminogen activator production in vascular endothelial cells. J Thromb Thrombolysis 35: 185-192.

18Larsson P, et al. (2012) Role of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue-type plasminogen activator expression. PLoS One7: 31573.

19Svennerholm K, et al. (2014) Histone deacetylase inhibitor treatment increases coronary t-PA release in a porcine ischemia model. PLoS One 9: 97260.

20Larsson P, et al. (2016) Valproic acid selectively increases vascular endothelial tissue-type plasminogen activator production and reduces thrombus formation in the mouse. J Thromb Haemost 14: 2496-2508.

21Saluveer O, et al. (2014) Profibrinolytic effect of the epigenetic modifier valproic acid in man. PLoS One 9: 107582.

22Svennerholm K, et al. (2015) Histone deacetylase inhibition enhances tissue plasminogen activator release capacity in atherosclerotic man. PLoS One 10: 0121196.

23Brookes RL, et al. (2018) Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack. Stroke 49: 54-61.

24Olesen JB, et al. (2011) Valproate attenuates the risk of myocardial infarction in patients with epilepsy: a nationwide cohort study. Pharmacoepidemiol Drug Saf 20: 146-53.

25Dregan A, et al. (2014) Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study. Pharmacoepidemiol Drug Saf 23: 759-67.

26Olesen JB, et al. (2011) Effects of epilepsy and selected antiepileptic drugs on the risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study. Pharmacoepidemiol Drug Saf 20: 964-971.

27Loscher W (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16: 669-94.

28Cannon CP, et al. (1997) Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Am J Cardiol 79: 253-258.

29Scheer FA, SA Shea (2014) Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle. Blood 123: 590-593.

30European Pharmacopeia (2005) Disintegration of tablets and capsules.

31Bostrom J, et al. (2013) Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid. J Med Chem 56: 3273-2380.

32Leppik IE, CA Hovinga (2013) Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations. Epilepsia 54: 28-35.

33Eriksson H, et al. (2007) CPU inhibition with AZD9684: profibrinolytic effects in acute patients. J Thromb Haemost 5 Supplement 2: 367.

34Cieslik J, et al. (2018) Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study. Blood 131: 797-807.

35Karasu A, et al. (2016) Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis. Br J Haematol 172: 947-953.

36Traby L, et al. (2012) Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. PLoS One 7: 51447.

37Undas A, (2017) Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence. Biomed Res Int 8196256.

38Undas A, M Zabczyk (2018) Antithrombotic medications and their impact on fibrin clot structure and function. J Physiol Pharmacol 69.

39Zabczyk M, J Majewski, J Lelakowski, ( 2 0 1 1) Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation. Pol Arch Med Wewn 121: 400-407.

40Sumaya W, et al. (2018) Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J 39: 1078-1085.

41Ajjan RA, et al. (2009) Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol 29: 712-717.

42Lau YC, et al. (2016) Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation. J Thromb Thrombolysis 42: 535-544.

43(2018) National Institue for Health and Care Excellence. British National Formulary.

44Bishton MJ, et al. (2011) Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 117: 3658-3668.

45Nasreddine WA (2008) Beydoun, Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia 49: 438-445.

46Koenig S, et al. (2008) High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagul Fibrinolysis 19: 375-382.